These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 16170185

  • 1. Raf: a strategic target for therapeutic development against cancer.
    Beeram M, Patnaik A, Rowinsky EK.
    J Clin Oncol; 2005 Sep 20; 23(27):6771-90. PubMed ID: 16170185
    [Abstract] [Full Text] [Related]

  • 2. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ, Der CJ.
    Oncogene; 2007 May 14; 26(22):3291-310. PubMed ID: 17496923
    [Abstract] [Full Text] [Related]

  • 3. Regulation of c-Raf-1: therapeutic implications.
    Beeram M, Patnaik A, Rowinsky EK.
    Clin Adv Hematol Oncol; 2003 Aug 14; 1(8):476-81. PubMed ID: 16258435
    [Abstract] [Full Text] [Related]

  • 4. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug 14; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 5. Raf pathway inhibitors in oncology.
    Bollag G, Freeman S, Lyons JF, Post LE.
    Curr Opin Investig Drugs; 2003 Dec 14; 4(12):1436-41. PubMed ID: 14763129
    [Abstract] [Full Text] [Related]

  • 6. RAF protein-serine/threonine kinases: structure and regulation.
    Roskoski R.
    Biochem Biophys Res Commun; 2010 Aug 27; 399(3):313-7. PubMed ID: 20674547
    [Abstract] [Full Text] [Related]

  • 7. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul 27; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 8. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV, Robertson GP.
    Cancer Res; 2008 Jan 01; 68(1):5-8. PubMed ID: 18172288
    [Abstract] [Full Text] [Related]

  • 9. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
    Burger M, Denzinger S, Hammerschmied C, Tannapfel A, Maderstorfer A, Wieland WF, Hartmann A, Stoehr R.
    Eur Urol; 2006 Nov 01; 50(5):1102-9; discussion 1109-10. PubMed ID: 16413100
    [Abstract] [Full Text] [Related]

  • 10. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C, Settleman J.
    Cancer Lett; 2009 Oct 08; 283(2):125-34. PubMed ID: 19217204
    [Abstract] [Full Text] [Related]

  • 11. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
    Friday BB, Adjei AA.
    Clin Cancer Res; 2008 Jan 15; 14(2):342-6. PubMed ID: 18223206
    [Abstract] [Full Text] [Related]

  • 12. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA, DeNicola GM, Winter SP, Tuveson DA.
    Mol Cell; 2009 Nov 13; 36(3):477-86. PubMed ID: 19917255
    [Abstract] [Full Text] [Related]

  • 13. Hyperactive Ras in developmental disorders and cancer.
    Schubbert S, Shannon K, Bollag G.
    Nat Rev Cancer; 2007 Apr 13; 7(4):295-308. PubMed ID: 17384584
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L, Trail PA, Taylor I, Wilhelm SM.
    Methods Enzymol; 2006 Apr 13; 407():597-612. PubMed ID: 16757355
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K.
    Cancer Res; 2009 Aug 15; 69(16):6515-21. PubMed ID: 19638574
    [Abstract] [Full Text] [Related]

  • 16. Raf kinase inhibitors in oncology.
    Strumberg D, Seeber S.
    Onkologie; 2005 Feb 15; 28(2):101-7. PubMed ID: 15665559
    [Abstract] [Full Text] [Related]

  • 17. Second nature: biological functions of the Raf-1 "kinase".
    Baccarini M.
    FEBS Lett; 2005 Jun 13; 579(15):3271-7. PubMed ID: 15943972
    [Abstract] [Full Text] [Related]

  • 18. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R, Piperdi S, Gorlick R.
    Clin Cancer Res; 2008 Oct 15; 14(20):6396-404. PubMed ID: 18927278
    [Abstract] [Full Text] [Related]

  • 19. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
    Garnett MJ, Rana S, Paterson H, Barford D, Marais R.
    Mol Cell; 2005 Dec 22; 20(6):963-9. PubMed ID: 16364920
    [Abstract] [Full Text] [Related]

  • 20. B-Raf kinase inhibitors for cancer treatment.
    Li N, Batt D, Warmuth M.
    Curr Opin Investig Drugs; 2007 Jun 22; 8(6):452-6. PubMed ID: 17621874
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.